Loading clinical trials...
Loading clinical trials...
Prospective, Observational, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation (ANIMA-R)
ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).
The index date will be the date of secukinumab initiation. During the study, data will be collected from patients receiving routine secukinumab treatment, which is representative of the actual patient population. The attending physician will decide whether to prescribe secukinumab based on the approved instructions for medical use in a routine clinical setting, regardless of the patient's participation in a non-interventional study.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
Novartis Investigative Site
Izhevsk, Russia
Novartis Investigative Site
Kaliningrad, Russia
Novartis Investigative Site
Kaliningrad, Russia
Novartis Investigative Site
Kazan', Russia
Novartis Investigative Site
Kemerovo, Russia
Novartis Investigative Site
Krasnodar, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Start Date
July 26, 2024
Primary Completion Date
August 31, 2026
Completion Date
August 31, 2026
Last Updated
December 1, 2025
300
ESTIMATED participants
Secukinumab
OTHER
Novartis Pharmaceuticals
CONTACT
Lead Sponsor
Novartis Pharmaceuticals
NCT06993233
NCT06888193
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07316192